Kailera Therapeutics Inc IPO unlock schedule & public float
Lock-up schedule, public float and locked shares extracted from Kailera Therapeutics Inc's SEC prospectus. Shares shown are eligible to trade — lock-up expiry does not mean holders have sold or will sell.
Shares eligible to trade · by holder groupApr 17, 2026 → Oct 14, 2026 · 100% unlocked
Lock-up holders84.62M
IPO public float39.06M
About Kailera Therapeutics Inc
Kailera Therapeutics Inc is a healthcare and life-sciences company with a business profile centered on medical products, therapies, diagnostics, or health-related services.
What the company does
Develops healthcare products, therapies, devices, or services where clinical evidence and regulatory execution are central to the business.
Operates in a market shaped by product differentiation, development timelines, reimbursement or customer adoption, and disciplined capital allocation.
Relies on technical, clinical, commercial, and operational teams to move products from development toward broader use.
Business profile
Kailera Therapeutics Inc belongs to the healthcare and life-sciences market, where product evidence, regulatory pathways, customer adoption, and funding discipline shape long-term outcomes.
SEC IPO filings
Final prospectus
EDGAR filings resolved from KLRA / CIK 0002096997.
Kailera reported first-quarter 2026 financial results and provided clinical data updates, including initiation of the global KaiNETIC Phase 3 program for ribupatide injection and topline/data updates from programs conducted by partner Hengrui in China. The release also stated IPO proceeds are expected to fund operations into mid-2028.
Kailera Therapeutics Inc completed its IPO on Apr 17, 2026 on NASDAQ Global Select under the ticker KLRA and now trades publicly.
What was Kailera Therapeutics Inc's IPO price?
Kailera Therapeutics Inc priced its IPO at $16.00 per share.
Can I buy Kailera Therapeutics Inc stock?
Yes — Kailera Therapeutics Inc is publicly traded on NASDAQ Global Select as KLRA. You can follow its live price, valuation and post-IPO performance above.
What is Kailera Therapeutics Inc's valuation?
Kailera Therapeutics Inc's most recent valuation tracked here is $2.96B, derived from live market prices.
